Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Diabetes and Vascular Disease Research
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hanefeld, M.
Right arrow Articles by Chiasson, J.-L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hanefeld, M.
Right arrow Articles by Chiasson, J.-L.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Diabetes
*Metabolic Syndrome
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Metabolic syndrome and its single traits as risk factors for diabetes in people with impaired glucose tolerance: the STOP-NIDDM trial

Markolf Hanefeld

Centre for Clinical Studies, GWT-TUD GmbH, Fiedlerstr. 34, 01307 Dresden, Germany.

Avraham Karasik

Institute of Endocrinology, Chaim Sheba Medical Centre, Tel Hashomer, Israel.

Carsta Koehler

Centre for Clinical Studies, GWT-TUD GmbH, Fiedlerstr. 34, 01307 Dresden, Germany.

Torsten Westermeier

Bayer Vital GmbH, Gebäude D162, 51368 Leverkusen, Germany.

Jean-Louis Chiasson

Department of Medicine, University of Montreal, Montreal, QC, Canada.

The STOP-NIDDM trial was an international, double-blind, placebo-controlled randomised study in people with impaired glucose tolerance (IGT). They were treated with an {alpha}-glucosidase inhibitor, acarbose, to prevent diabetes; the overall number needed to treat (NNT) was 11.

In a secondary analysis, we considered the impact of single traits and overall metabolic syndrome (MetS) respectively on risk of diabetes and NNT respectively.

In all, there were 1,368 patients. They were followed up for 3.3 years, and the prevalence of MetS was 61%. Multivariate analysis revealed treatment group 2-hour (post-challenge) plasma glucose, glycosylated haemoglobin (HbA1C), triglycerides and leukocyte count as independent predictors. The annual incidence of diabetes in the placebo group with MetS was 18.7% vs. 11.2% in patients without MetS; the corresponding figures in the acarbose group were 13.5% and 9.4%, respectively. The NNT in patients was 5.8 in patients with MetS and 16.5 in those without MetS.

In conclusion, most single traits and overall MetS label a very high-risk group in people with IGT. People with MetS reach a NNT to prevent development of new diabetes with acarbose of 5.8.

Trial-Number: NCT00629213//ClinicalTrials.gov

Key Words: acarbose • impaired glucose tolerance • metabolic syndrome • primary prevention • risk factors

Diabetes and Vascular Disease Research, Vol. 6, No. 1, 32-37 (2009)
DOI: 10.3132/dvdr.2009.006
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?